08:14 AM EDT, 05/29/2024 (MT Newswires) -- Immunocore Holdings ( IMCR ) said Wednesday a phase 2/3 trial evaluating its therapy candidate, Kimmtrak as a monotherapy and in combination with pembrolizumab to treat certain patients with skin cancer has been converted into a phase 3 trial.

The decision comes following a consultation with the US Food and Drug Administration, the company said, adding it now plans to conduct the trial solely as a phase 3 with the primary endpoint of overall survival.

With the conversion of the trial, the final analysis will be accelerated, the company said.

Price: 46.81, Change: +0.51, Percent Change: +1.10